The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature

Transplantation

Volumn 100, Issue 11, 2016, Pages 2309-2314

  Munneke, J Marius ^a   Spruit, Melchior J A ^a   Cornelissen, Anne S ^a   Van Hoeven, Vera ^a   Voermans, Carlijn ^a   Hazenberg, Mette D ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CYCLOSPORIN; INFLIXIMAB; MYCOPHENOLATE MOFETIL; PENTOSTATIN; PREDNISOLONE; PSORALEN; THYMOCYTE ANTIBODY; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL TRANSPLANTATION; DISEASE COURSE; DISEASE SEVERITY; EXTRACORPOREAL PHOTOPHERESIS; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STROMA CELL TRANSPLANTATION; OVERALL SURVIVAL; PATIENT SELECTION; PHOTOPHERESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEVERE STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; ACUTE DISEASE; ADVERSE EFFECTS; GRAFT VS HOST DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION;

ACUTE DISEASE; GRAFT VS HOST DISEASE; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; STEROIDS;

EID: 84952064519     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001029     Document Type: Review

References (38)

1. Garnett C, Apperley JF, Pavlu J. Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol. 2013;4:366-378.
2. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109:4119-4126.
3. Jamani K, Russell JA, Daly A, et al. Prognosis of grade 3-4 acute GVHD continues to be dismal. Bone Marrow Transplant. 2013;48:1359-1361.
4. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood. 2003;102:2768-2776.
5. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high-or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998;92:2288-2293.
6. Cragg L, Blazar BR, Defor T, et al. A randomized trial comparing predni-sone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6:441-447.
7. Lee SJ, Zahrieh D, Agura E, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004;104:1559-1564.
8. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439-1441.
9. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002;30:42-48.
10. Friedenstein AJ, Petrakova KV, Kurolesova AL, et al. Heterotopic transplants of bone marrow. Transplantation. 1968;6:230.
11. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.
12. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317.
13. Young RG, Butler DL, Weber W, et al. Use of mesenchymal stem cells in a collagen matrix for Achilles tendon repair. J Orthop Res. 1998;16:406-413.
14. Wakitani S, Goto T, Pineda SJ, et al. Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. J Bone Joint Surg Am. 1994;76:579-592.
15. De Bari C, Dell'Accio F, Vandenabeele F, et al. Skeletal muscle repair by adult human mesenchymal stem cells from synovial membrane. J Cell Biol. 2003;160:909-918.
16. Zhao K, Lou R, Huang F, et al. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21:97-104.
17. Ringdén O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006;81:1390-1397.
18. Fang B, Song Y, Liao L, et al. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc. 2007;39:3358-3362.
19. Resnick IB, Barkats C, Shapira MY, et al. Treatment ofsevere steroid resistant acute GVHD with mesenchymal stromal cells (MSC).Am J Blood Res. 2013;3:225-238.
20. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579-1586.
21. Bonin von M, Stölzel F, Goedecke A, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009;43:245-251.
22. Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20:1580-1585.
23. Te Boome LC, Mansilla C, van der Wagen LE, et al. Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells. In: Leukemia. 2015;29:1839-1846.
24. Introna M, Lucchini G, Dander E, et al. Treatment of graft versus host dis-ease with mesenchymal stromal cells: a phase I study on 40 adult and pe-diatric patients. Biol Blood Marrow Transplant. 2014;20:375-381.
25. Paulson K, Saeed M, Mills J, et al. Publication bias is present in blood and marrow transplantation: an analysis of abstracts at an international meeting. Blood. 2011;118:6698-6701.
26. Galipeau J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy. 2013;15:2-8.
27. Wu KH, Chan CK, Tsai C, et al. Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mes-enchymal stem cells. Transplantation. 2011;91:1412-1416.
28. Ringdén O, Erkers T, Nava S, et al. Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease. Stem Cells. 2013;31: 592-601.
29. Neofytou E, Deuse T, Beygui RE, et al. Mesenchymal stromal cell therapy: different sources exhibit different immunobiological properties. Transplantation. 2015;99:1113-1118.
30. Melief SM, Zwaginga JJ, Fibbe WE, et al. Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med. 2013; 2:455-463.
31. Ivanova-Todorova E, Bochev I, Mourdjeva M, et al. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett. 2009;126:37-42.
32. Hanash AM, Dudakov JA, Hua G, et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity. 2012;37:339-350.
33. Munneke JM, Björklund AT, Mjösberg JM, et al. Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. Blood. 2014;124:812-821.
34. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-gamma inthe im-munomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386-398.
35. François M, Romieu-Mourez R, Li M, et al. Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther. 2012;20: 187-195.
36. Polchert D, Sobinsky J, Douglas G, et al. IFN-gamma activation ofmesen-chymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008;38:1745-1755.
37. Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distrib-ute to a wide range of tissues following systemic infusion into nonhuman primates. Blood. 2003;101:2999-3001.
38. Maijenburg MW, van der Schoot CE, Voermans C. Mesenchymal stromal cell migration: possibilities to improve cellular therapy. Stem Cells Dev. 2012;21:19-29.